| Nov 15 |
Pluri First Quarter 2025 Earnings: US$1.08 loss per share (vs US$0.96 loss in 1Q 2024)
|
| Oct 28 |
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
|
| Jul 18 |
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
|
| Jul 8 |
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
|
| Jun 18 |
Pluri: Biotech Play With Several Opportunities Across Different Sectors
|
| Jun 18 |
Pluri subsidiary Ever After Foods secures $10M strategic investment
|
| Jun 18 |
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
|
| Jun 6 |
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
|
